![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Research Insight
Manhattan Research’s ePharma Consumer study provides in-depth info about pharma product websites
Pharmaceutical and healthcare market research company Manhattan Research recently released the ePharma Consumer® v10.0 study, which explores the online behaviors of ePharma Consumers, or...
Research Insight
Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study
Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for...
Research Insight
Pro-Pharmaceuticals and Mount Sinai annouced New Liver Fibrosis Research Collaboration
Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with...
Research Insight
New data show potential for Novartis Meningitis B vaccine candidate to cover majority of diverse meningococcal serogroup B strains
New data demonstrated that antibodies induced by Novartis Vaccines investigational, four component, Meningococcal Serogroup B Vaccine (4CMenB) killed the majority of a collection of...
Research Insight
University of Rochester Spearheads FDA Initiative to Speed Development of New Therapies
Pain is the most common symptom leading patients to see a physician in the United States, yet the most widely prescribed medications – opioids...
Research Insight
Phase II Study with Ocrelizumab Shows Significant Reduction in Disease Activity for Multiple Sclerosis Patients
Genentech, Inc., a member of the Roche Group, and Biogen Idec announced 24-week results1 from a phase II study of ocrelizumab in patients with...
Research Insight
21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with Betaferon Treatment
New findings from the longest assessment of any MS-specific treatment show that patients treated earlier with Betaferon® (interferon beta-1b) had a 39.3% relative reduced...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read